COIOSDeep risk insights through multi-disciplinary research across the globe
A bright stationery store interior with shelves of greeting cards and office supplies
Item new Peer-reviewed Added

Adults with obesity and asthma on GLP-1 drugs had fewer recorded exacerbations

In 2,423 matched pairs of adults with obesity and asthma, one-year recorded asthma exacerbation was 1.7% on GLP-1 therapy as compared to 4.0% on other weight-management drugs.

A retrospective cohort in the TriNetX US network compared 2,423 matched pairs of adults with obesity and asthma, on GLP-1 therapy or other weight-management drugs. Over one year, recorded asthma exacerbation occurred in 1.7% of the GLP-1 arm as compared to 4.0% of the comparator arm. Emergency or critical-care use was 7.1% as compared to 13.0%, although the authors state that residual confounding precludes causal inference.

Why it is interesting: A respiratory outcome for GLP-1 therapy from routine care, in a design that cannot separate effect from selection.

Source
Expert Review of Respiratory Medicine, 13 September 2026
Paper
Association of GLP-1-based therapy with asthma-related outcomes in patients with obesity: a propensity-matched retrospective cohort study
Authors
McCraw CD, Grayeb DR, Gupta N, Zafar P, Javed A, Kainat et al.
DOI
10.1080/17476348.2026.2730537
Type
Peer-reviewed article
Design
Retrospective active-comparator cohort in TriNetX US network, 1:1 propensity-matched, 2,423 per arm, one-year follow-up
Verdict
New finding
Driver
Obesity, diabetes and GLP-1

Other drivers in Health today